ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

EPIVIR
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

EPIVIR Rx

Generic Name and Formulations:
Lamivudine 150mg (+), 300mg; tabs; (+) scored.

Company:
ViiV Healthcare

Therapeutic Use:

Indications for EPIVIR:

HIV-1 infection, in combination with other antiretrovirals.

Adult:

CrCl ≥50mL/min: 300mg once daily or 150mg twice daily; CrCl 30–49mL/min: 150mg once daily; CrCl 15–29mL/min: 150mg for 1st dose then 100mg once daily; CrCl 5–14mL/min: 150mg for 1st dose then 50mg once daily; CrCl <5mL/min: 50mg for 1st dose then 25mg once daily.

Children:

<3 months: not established. ≥3 months (oral soln): 4mg/kg twice daily or 8mg/kg once daily; max 300mg/day. Tabs: 14–<20kg: 150mg once daily or 75mg twice daily; ≥20–<25kg: 225mg once daily or 75mg in the AM and 150mg in the PM; ≥25kg: 300mg once daily or 150mg twice daily. Renal impairment: consider dose reduction and/or increase dosing interval.

Warnings/Precautions:

Not interchangeable with Epivir-HBV. Women, obesity, or prolonged nucleoside exposure: increased risk of lactic acidosis, hepatomegaly with steatosis. Other liver disease risk factors. Suspend therapy if lactic acidosis or pronounced hepatotoxicity (including hepatomegaly, steatosis) occurs. Hepatitis B virus co-infection: monitor for post-treatment exacerbation, emergence of lamivudine-resistant HBV variants. Children with prior antiretroviral nucleoside exposure, history of pancreatitis or risk factors for pancreatitis. Discontinue if signs/symptoms of pancreatitis occurs. Oral soln: lower virologic suppression rates and increased risk of viral resistance. Pregnancy. Nursing mothers: not recommended.

Interactions:

Concomitant zalcitabine: not recommended. Avoid concomitant drugs that contain lamivudine or emtricitabine. Caution with drugs eliminated by active organic cationic secretion (eg, trimethoprim). Triple therapy (once daily regimen) with abacavir + tenofovir or with didanosine + tenofovir: high rate of early viral non-response (see full labeling). Monitor for treatment-associated toxicities (esp. hepatic decompensation) with interferon-alpha with or without ribavirin.

See Also:

EPIVIR ORAL SOLUTION

Pharmacological Class:

Nucleoside analogue (reverse transcriptase inhibitor).

Adverse Reactions:

Adults: headache, malaise, fatigue, fever, nausea, diarrhea, nasal signs/symptoms, cough, neuropathy, dizziness, sleep or depressive disorders, rash, musculoskeletal pain; lactic acidosis, severe hepatomegaly with steatosis, fat redistribution, immune reconstitution syndrome, neutropenia, abnormal liver enzymes. Children: fever, cough, rash; pancreatitis, paresthesias, peripheral neuropathy, neutropenia, abnormal liver enzymes.

Note:

Register pregnant patients exposed to lamivudine by calling (800) 258-4263.

Generic Availability:

YES

How Supplied:

Tabs 150mg—60; 300mg—30; Soln—240mL

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs